This gene overview is brought to you as part of Tempus’ goal to inform providers about our genomic testing panels and the genes included in our offerings. Through our robust de-identified database of clinical information coupled with molecular testing results, we are capable of providing unique insights into these gene alterations. Many of the gene alterations reported on our somatic and germline panels are often key inclusion criteria for clinical trials.

ATM Gene

A-T Mutated

The ATM gene is a member of the PI3/PI4-kinase gene family. The ATM gene functions as a cell cycle checkpoint kinase, controlling the rate of cell growth and division. Additionally, it assists in the repair of damaged DNA. Loss of function mutations, copy number loss, and underexpression of ATM are associated with cancer progression.

ATM alterations in 10 most common cancers – Tempus database

image description
The above graph is representative of the 3.8M+ de-identified patient records in the Tempus database as of September 30, 2021.

FDA approved drugs for ATM mutated cancers

TherapyTumor type (indication)Biomarker
LYNPARZA® olaparib Prostate cancer HRR genes including ATM
As of September 30, 2021. HRD – homologous recombination deficiency; RR – response rate; mPFS – median PFS; mOS – median OS in months; mDOR - duration of response in months; NE - not evaluated, NR - not reached.

Some strategies in clinical development targeting ATM pathway

View a more comprehensive list of clinical trials for patients with ATM mutated cancers. The Tempus TIME Trial ® Program brings the right clinical trial options directly to patients, for enrollment at your institution. Learn more

Additional resources for ATM gene:

Additional resources on variants:

Join the movement

We are committed to helping advance cancer treatment for patients. We believe that every new test is an investment in the development of patient care for the future.